nanotech-investing Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property for Patent Covering Breast Cancer Vaccine Technology
nanotech-investing Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
nanotech-investing Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
nanotech-investing Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
nanotech-investing Anixa Biosciences Announces World Health Organization Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
nanotech-investing Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
nanotech-investing Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
nanotech-investing Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
nanotech-investing Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
nanotech-investing Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
nanotech-investing Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
nanotech-investing Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
nanotech-investing Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
nanotech-investing Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
